IL13 and asthma: Anti-IL-13 agents, such as lebrikizumab or tralokinumab, are also being investigated for asthma, in addition to COPD, due to their involvement in mediating T-cell responses after their release from ILCs and in mediating airway hypersensitivity [149,150].